title: Raltegravir: is a 400 mg once-daily dose enough?
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Lanzafame
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.forename: Emanuela
authors.initials: E
authors.lastname: Lattuada
authors.forename: Andrea
authors.initials: A
authors.lastname: Calcagno
authors.forename: Stefano
authors.initials: S
authors.lastname: Bonora
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D006678:HIV / Q000302:isolation & purification; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011760:Pyrrolidinones / Q000008:administration & dosage*; D000068898:Raltegravir Potassium; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium